is a biopharmaceutical company focused on the development of
novel treatments for B-cell malignancies and autoimmune diseases.
Click for full image >>
TG Therapeutics Announces Double & Triple Combination Therapy Data Presentations at the 58th American Society of Hematology Annual Meeting
TG Therapeutics, Inc. Announces that the GENUINE Phase 3 Study has Reached Target Enrollment
2 Gansevoort Street, 9th Floor, New York NY 10014 - P:212.554.4484 - Email Us
Web Site Development by Tidal Media Group